Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

17 Dec 2019

Abstract excerpt

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC) tumors beyond the administration of chemotherapy, and very recently, the approval of the anti PD-L1 inhibitor atezolizumab. Neoadjuvant chemotherapy is currently the standard of care treatment in the early stage disease, although reliable biomarkers of response have been scarcely described. In our study we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31921107
DOI: 10.3389/fimmu.2019.02802

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast TumorsPMID 31921107Read ↗

Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumorsSemantic proximity Read ↗

The expression profiles of signature genes from CD103+LAG3+ tumour-infiltrating lymphocyte subsets predict breast cancer survivalSemantic proximity Read ↗

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancerSemantic proximity Read ↗

Interleukin-17-based cytokine signaling as a determinant for tumor immune microenvironment with prognostic value in triple-negative breast cancerSemantic proximity Read ↗

Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.Semantic proximity Read ↗

Tumor-Infiltrating Lymphocytes Display Prognostic Signatures Associated with Chemotherapy Response in TNBC PatientsSemantic proximity Read ↗

Identification of a Gene Panel Predictive of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy Employing Transcriptomic and Functional ValidationSemantic proximity Read ↗

Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity Read ↗

Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancerSemantic proximity Read ↗

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancerSemantic proximity Read ↗

Machine learning-driven identification and immunohistochemical validation of an integrated immune-inflammatory phenotype for disease-free survival stratification in breast cancer.Semantic proximity Read ↗

Predictive Value of Immune Genomic Signatures from Breast Cancer Cohorts Containing Data for Both Response to Neoadjuvant Chemotherapy and Prognosis after SurgerySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.